Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer

Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer

Bibliographic Details
Main Authors:	Wada, Satoshi, Jackson, Christopher M, Yoshimura, Kiyoshi, Yen, Hung-Rong, Getnet, Derese, Harris, Timothy J, Goldberg, Monica V, Bruno, Tullia C, Grosso, Joseph F, Durham, Nicholas, Netto, George J, Pardoll, Drew M, Drake, Charles G
Format:	Online
Language:	English
Published:	BioMed Central 2013
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666941/

Similar Items

Immunotherapy earns its spot in the ranks of cancer therapy
by: Pardoll, Drew, et al.
Published: (2012)

Combination Immunotherapy with 4-1BBL and CTLA-4 Blockade for the Treatment of Prostate Cancer
by: Youlin, Kuang, et al.
Published: (2012)

Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
by: Fan, Xiaozhou, et al.
Published: (2014)

Combination immunotherapy with Interleukin-2 and CTLA-4 blockade decreases tumor growth and improves overall survival
by: Broucek, Joseph R, et al.
Published: (2013)

Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?
by: Fei Tang, et al.
Published: (2018-04-01)

Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma
by: Janet Retseck, et al.
Published: (2018-07-01)

Immunotherapies: The Blockade of Inhibitory Signals
by: Wu, Yan-Ling, et al.
Published: (2012)

Immunotherapies: The Blockade of Inhibitory Signals
by: Yan-Ling Wu, Jing Liang, Wen Zhang, Yoshimasa Tanaka, Hiroshi Sugiyama
Published: (2012-01-01)

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
by: Peggs, Karl S., et al.
Published: (2009)

Protective Immunity to Nematode Infection Is Induced by CTLA-4 Blockade
by: McCoy, Kathy, et al.
Published: (1997)

CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection
by: Waitz, Rebecca, et al.
Published: (2012)

Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models
by: Jure-Kunkel, Maria, et al.
Published: (2013)

S43. Dendritic cell vaccination combined with CTLA4 blockade
by: Thielemans, K, et al.
Published: (2014)

CTLA-4 checkpoint blockade in breast cancer, a case in point report
by: Dellepiane, Chiara, et al.
Published: (2015)

CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations
by: Camacho, Luis H
Published: (2015)

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
by: Callahan, Margaret K., et al.
Published: (2015)

Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model
by: Belcaid, Zineb, et al.
Published: (2014)

Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells
by: Foy, Susan P., et al.
Published: (2016)

Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma
by: Lussier, Danielle M, et al.
Published: (2015)

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
by: Heinzerling, Lucie, et al.
Published: (2016)

Phenotypic and Functional Properties of Helios+ Regulatory T Cells
by: Zabransky, Daniel J., et al.
Published: (2012)

Immune-Checkpoint Blockade and Active Immunotherapy for Glioma
by: Ahn, Brian J., et al.
Published: (2013)

Patients with chronic lymphocytic leukaemia (CLL) differ in the pattern of CTLA-4 expression on CLL cells: the possible implications for immunotherapy with CTLA-4 blocking antibody
by: Ciszak, Lidia, et al.
Published: (2015)

Cyclic dinucleotides (CDNs) reversed T cells tolerance in anti-tumor immunotherapy
by: Fu, Juan, et al.
Published: (2015)

Combination immunotherapy: Where do we go from here?
by: Overacre, Abigail E., et al.
Published: (2015)

Primer on tumor immunology and cancer immunotherapy
by: Harris, Timothy J, et al.
Published: (2013)

CTLA-4 blockade during dendritic cell based booster vaccination influences dendritic cell survival and CTL expansion
by: Pedersen, Anders E, et al.
Published: (2007)

Blockade ofthe negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis
by: Chang, Katherine C, et al.
Published: (2013)

Synergistic Effect of CTLA-4 Blockade and Cancer Chemotherapy in the Induction of Anti-Tumor Immunity
by: Lesterhuis, W. Joost, et al.
Published: (2013)

Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell–mediated glioma rejection
by: vom Berg, Johannes, et al.
Published: (2013)

Stereotactic body radiation therapy and CTLA-4 blockade as a novel therapy for advanced melanoma
by: Twyman, Christina, et al.
Published: (2013)

Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo
by: Sandin, Linda C, et al.
Published: (2014)

Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management
by: Tarhini, Ahmad
Published: (2013)

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment
by: Edmund Poon, et al.
Published: (2017-08-01)

Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade
by: Sara Valpione, et al.
Published: (2018-04-01)

Co-Stimulatory Blockade of the CD28/CD80-86/CTLA-4 Balance in Transplantation: Impact on Memory T Cells?
by: Ville, Simon, et al.
Published: (2015)

Distinct immunologic changes in vivo following combination versus individual PD-1 or CTLA-4 checkpoint blockade in human cancer
by: Dhodapkar, Kavita, et al.
Published: (2014)

Reversing gp100/IFA-induced impairment of anti-CTLA-4 checkpoint blockade therapy
by: Hailemichael, Yared, et al.
Published: (2014)

Unique changes in the TCR repertoire of tumor-infiltrating lymphocytes underlie the synergy of radiotherapy with CTLA-4 blockade
by: Pilones, Karsten, et al.
Published: (2014)

Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes
by: Robert, Lidia, et al.
Published: (2014)